시퀀싱 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 용도별, 워크플로우별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Sequencing Market Growth & Trends:

The global sequencing market size is anticipated to reach USD 62.48 billion by 2030, growing at a CAGR of 22.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing investments by governments and private organizations in genomic research and development and the increasing demand for personalized medicine and precision treatments have led to a rise in the adoption of these technologies, which are expected to boost the market further. For instance, in December 2022, the UK government announced a USD 222.36 million investment in genomics research in partnership with the National Health Service (NHS). This investment aimed to explore the effectiveness of using whole-genome sequencing to treat and find rare genetic diseases in newborn babies.

The rising number of infectious diseases such as Campylobacter infection, Hepatitis A, B, C, HIV, Influenza (Flu), and Meningococcal disease has been a major driver of the market. According to WHO, in 2022, 39 million people are living with HIV. As per the Hepatitis B Foundation, approximately 1.5 million people are newly infected due to hepatitis B each year. As the number of outbreaks and epidemics increases, there is a growing demand for accurate and rapid sequencing technologies that can help identify the pathogens responsible for these diseases. With the advancement of technologies, it has become easier and faster to sequence the genomes of pathogens, enabling healthcare providers and researchers to understand the spread of these diseases better and develop targeted treatments and vaccines. As a result, the market is expected to continue to grow in the coming years, driven by the need to combat infectious diseases and improve global health.

The COVID-19 pandemic has had a significant impact on the market. With the rapid spread of the virus, there has been an increased demand for these technologies to understand the virus better and track its mutations. This has led to a surge in demand for sequencing instruments, reagents, and services. However, the pandemic has also disrupted supply chains and caused delays in research projects, which has had a negative impact on the market growth.

The market faces several challenges, including high costs associated with sequencing and data analysis, limited accuracy and reliability of these technologies, and difficulties in managing and interpreting large amounts of data generated by sequencing. In addition, there are concerns regarding data privacy and ethical implications related to sequencing genetic information. There is still a need for standardization and quality control in sequencing, improved accessibility, and affordability for researchers and clinicians.

Sequencing Market Report Highlights:

• Consumables dominated the product & service segment with more than 44.5% share in 2023 owing to the increasing demand for sequencing in research and diagnostics, which has resulted in the development of new and improved consumables
• In application segment, oncology held the largest market share in 2023. On the other hand, metagenomics, epidemiology & drug development is expected to grow at the fastest CAGR
• In 2023, sequencing dominated the workflow segment, and data analysis is expected to at the fastest CAGR
• Academic research dominated the end-use segment with largest share in 2023 driven by a desire to advance knowledge and contribute to scientific interests, resulting in more innovative research
• North America dominated the sequencing market with a share of 49.4% owing to factors such as the significant burden of infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Application
  • 1.2.3. Workflow
  • 1.2.4. End-use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Increasing Cases of Cancer
    • 3.3.1.2. Technological advances in next-generation sequencing technologies
    • 3.3.1.3. High investment in research and development
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Lack of Skilled Professionals
    • 3.3.2.2. Legal and Ethical Issues
• 3.4. Industry Analysis Tools
  • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.4.2. Porter's Five Forces Analysis
  • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Sequencing market: Product & Services Business Analysis

• 4.1. Sequencing market: Product & Services Market Share Analysis
• 4.2. Sequencing market Estimates & Forecast, By Product & Services (USD Million)
• 4.3. Platform
  • 4.3.1. Global Platform Market, 2018 - 2030 (USD Million)
  • 4.3.2. 1st Generation of Sequencing Device
    • 4.3.2.1. Global 1st Generation of Sequencing Device Market, 2018 - 2030 (USD Million)
  • 4.3.3. 2nd Generation of Sequencing Device
    • 4.3.3.1. Global 2nd Generation of Sequencing Device Market, 2018 - 2030 (USD Million)
  • 4.3.4. 3rd Generation of Sequencing Device
    • 4.3.4.1. Global 3rd Generation of Sequencing Device Market, 2018 - 2030 (USD Million)
• 4.4. Consumables
  • 4.4.1. Global Consumables Market, 2018 - 2030 (USD Million)
  • 4.4.2. Kits
    • 4.4.2.1. Global Kits Market, 2018 - 2030 (USD Million)
    • 4.4.2.2. DNA Library Preparation
    • 4.4.2.2.1. Global DNA Library Preparation Market, 2018 - 2030 (USD Million)
    • 4.4.2.3. RNA Library Preparation
    • 4.4.2.3.1. Global RNA Library Preparation Market, 2018 - 2030 (USD Million)
    • 4.4.2.4. Target enrichment
    • 4.4.2.4.1. Global Target enrichment Market, 2018 - 2030 (USD Million)
    • 4.4.2.5. Library quantification
    • 4.4.2.5.1. Global Library quantification Market, 2018 - 2030 (USD Million)
    • 4.4.2.6. Purification & quality control
    • 4.4.2.6.1. Global Purification & quality control Market, 2018 - 2030 (USD Million)
    • 4.4.2.7. Others
    • 4.4.2.7.1. Global Others Market, 2018 - 2030 (USD Million)
  • 4.4.3. Reagents
    • 4.4.3.1. Global Reagents Market, 2018 - 2030 (USD Million)
    • 4.4.3.2. Sample Prep
    • 4.4.3.2.1. Global Sample Prep Market, 2018 - 2030 (USD Million)
    • 4.4.3.3. Library preparation and amplification
    • 4.4.3.3.1. Global Library preparation and amplification Market, 2018 - 2030 (USD Million)
    • 4.4.3.4. Sequencing
    • 4.4.3.4.1. Global Sequencing Market, 2018 - 2030 (USD Million)
  • 4.4.4. Accessories
    • 4.4.4.1. Global Accessories Market, 2018 - 2030 (USD Million)
    • 4.4.4.2. Collection tubes
    • 4.4.4.2.1. Global Collection tubes Market, 2018 - 2030 (USD Million)
    • 4.4.4.3. Plates
    • 4.4.4.3.1. Global Plates Market, 2018 - 2030 (USD Million)
    • 4.4.4.4. Others
    • 4.4.4.4.1. Global Others Market, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Global Services Market, 2018 - 2030 (USD Million)
• 4.6. Software
  • 4.6.1. Global Software Market, 2018 - 2030 (USD Million)

Chapter 5. Sequencing Market: Application Business Analysis

• 5.1. Sequencing Market: Application Market Share Analysis
• 5.2. Sequencing Market Estimates & Forecast, By Application (USD Million)
• 5.3. Oncology
  • 5.3.1. Global Oncology Market, 2018 - 2030 (USD Million)
  • 5.3.2. Diagnostics and Screening
    • 5.3.2.1. Global Diagnostics and Screening Market, 2018 - 2030 (USD Million)
  • 5.3.3. Oncology Screening
    • 5.3.3.1. Global Oncology Screening Market, 2018 - 2030 (USD Million)
    • 5.3.3.1.1. Sporadic Cancer
    • 5.3.3.1.1.1. Global Sporadic Cancer Market, 2018 - 2030 (USD Million)
    • 5.3.3.1.2. Inherited Cancer
    • 5.3.3.1.2.1. Global Inherited Cancer Market, 2018 - 2030 (USD Million)
  • 5.3.4. Companion Diagnostics
    • 5.3.4.1. Global Companion Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.3.5. Other Diagnostics
    • 5.3.5.1. Global Other Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.3.6. Research Studies
    • 5.3.6.1. Global Research Studies Market, 2018 - 2030 (USD Million)
• 5.4. Clinical Investigation
  • 5.4.1. Global Clinical Investigation Market, 2018 - 2030 (USD Million)
  • 5.4.2. Infectious Diseases
    • 5.4.2.1. Global Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.4.3. Inherited Diseases
    • 5.4.3.1. Global Inherited Diseases Market, 2018 - 2030 (USD Million)
  • 5.4.4. Idiopathic Diseases
    • 5.4.4.1. Global Idiopathic Diseases Market, 2018 - 2030 (USD Million)
  • 5.4.5. Non-Communicable/Other Diseases
    • 5.4.5.1. Global Non-Communicable/Other Diseases Market, 2018 - 2030 (USD Million)
• 5.5. Reproductive Health
  • 5.5.1. Global Reproductive Health Market, 2018 - 2030 (USD Million)
  • 5.5.2. NIPT
    • 5.5.2.1. Global NIPT Market, 2018 - 2030 (USD Million)
    • 5.5.2.2. Aneuploidy
    • 5.5.2.2.1. Global Aneuploidy Market, 2018 - 2030 (USD Million)
    • 5.5.2.3. Microdeletions
    • 5.5.2.3.1. Global Microdeletions Market, 2018 - 2030 (USD Million)
  • 5.5.3. PGT
    • 5.5.3.1. Global PGT Market, 2018 - 2030 (USD Million)
  • 5.5.4. Newborn Genetic Screening
    • 5.5.4.1. Global Newborn Genetic Screening Market, 2018 - 2030 (USD Million)
  • 5.5.5. Single Gene Analysis
    • 5.5.5.1. Global Single Gene Analysis Market, 2018 - 2030 (USD Million)
• 5.6. HLA Typing/Immune System Monitoring
  • 5.6.1. Global HLA Typing/Immune System Monitoring Market, 2018 - 2030 (USD Million)
• 5.7. Metagenomics, Epidemiology & Drug Development
  • 5.7.1. Global Metagenomics, Epidemiology & Drug Development Market, 2018 - 2030 (USD Million)
• 5.8. Agrigenomics & Forensics
  • 5.8.1. Global Agrigenomics & Forensics Market, 2018 - 2030 (USD Million)
• 5.9. Consumer Genomics
  • 5.9.1. Global Consumer Genomics Market, 2018 - 2030 (USD Million)

Chapter 6. Sequencing Market: Workflow Business Analysis

• 6.1. Sequencing Market: Workflow Market Share Analysis
• 6.2. Sequencing Market Estimates & Forecast, By Workflow (USD Million)
• 6.3. Pre-Sequencing
  • 6.3.1. Global Pre-sequencing Market, 2018 - 2030 (USD Million)
• 6.4. Sequencing
  • 6.4.1. Global Sequencing Market, 2018 - 2030 (USD Million)
• 6.5. Data Analysis
  • 6.5.1. Global Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 7. Sequencing Market: End-use Business Analysis

• 7.1. Sequencing market: End-use Market Share Analysis
• 7.2. Sequencing market Estimates & Forecast, By End-use (USD Million)
• 7.3. Academic Research
  • 7.3.1. Global Academic Research Market, 2018 - 2030 (USD Million)
• 7.4. Clinical Research
  • 7.4.1. Global Clinical Research Market, 2018 - 2030 (USD Million)
• 7.5. Hospitals & Clinics
  • 7.5.1. Global Hospitals & Clinics Market, 2018 - 2030 (USD Million)
• 7.6. Pharma & Biotech Entities
  • 7.6.1. Global Pharma & Biotech Entities Market, 2018 - 2030 (USD Million)
• 7.7. Other Users
  • 7.7.1. Global Other Users Market, 2018 - 2030 (USD Million)

Chapter 8. Sequencing Market: Regional Business Analysis

• 8.1. Sequencing Market Share, By Region, 2023 & 2030
• 8.2. North America
  • 8.2.1. North America Sequencing market, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Target Disease Prevalence
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. U.S. Sequencing market, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Target Disease Prevalence
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Canada Sequencing market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Target Disease Prevalence
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. UK Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Target Disease Prevalence
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Germany Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Target Disease Prevalence
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. France Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Target Disease Prevalence
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Italy Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Target Disease Prevalence
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Spain Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Target Disease Prevalence
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Denmark Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Target Disease Prevalence
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Sweden Sequencing market, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Target Disease Prevalence
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Norway Sequencing market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Sequencing market, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Target Disease Prevalence
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Japan Sequencing market, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Target Disease Prevalence
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. China Sequencing market, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Target Disease Prevalence
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. India Sequencing market, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Target Disease Prevalence
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Australia Sequencing market, 2018 - 2030 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Target Disease Prevalence
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Thailand Sequencing market, 2018 - 2030 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Target Disease Prevalence
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. South Korea Sequencing market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Sequencing market, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Target Disease Prevalence
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Brazil Sequencing market, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Target Disease Prevalence
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Mexico Sequencing market, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Target Disease Prevalence
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Argentina Sequencing market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Sequencing market, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Target Disease Prevalence
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. South Africa Sequencing market, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Target Disease Prevalence
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Saudi Arabia Sequencing market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Target Disease Prevalence
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. UAE Sequencing market, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Target Disease Prevalence
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Kuwait Sequencing market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Financial Performance
• 9.2. Participant Categorization
  • 9.2.1. Market Leaders
    • 9.2.1.1. Market share analysis, 2023
• 9.3. Participant's Overview
  • 9.3.1. Illumina, Inc.
    • 9.3.1.1. Overview
    • 9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.1.3. Technology Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. F. Hoffman-La Roche Ltd.
    • 9.3.2.1. Overview
    • 9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.2.3. Technology Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. QIAGEN
    • 9.3.3.1. Overview
    • 9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.3.3. Technology Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Thermo Fisher Scientific, Inc.
    • 9.3.4.1. Overview
    • 9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.4.3. Technology Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Bio-Rad Laboratories, Inc.
    • 9.3.5.1. Overview
    • 9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.5.3. Technology Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Oxford Nanopore Technologies
    • 9.3.6.1. Overview
    • 9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.6.3. Technology Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. PierianDx
    • 9.3.7.1. Overview
    • 9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.7.3. Technology Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Genomatix GmbH
    • 9.3.8.1. Overview
    • 9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.8.3. Technology Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. DNASTAR, Inc.
    • 9.3.9.1. Overview
    • 9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.9.3. Technology Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Perkin Elmer, Inc.
    • 9.3.10.1. Overview
    • 9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.10.3. Technology Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Eurofins GATC Biotech GmbH
    • 9.3.11.1. Overview
    • 9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.11.3. Technology Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. BGI
    • 9.3.12.1. Overview
    • 9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.3.12.3. Technology Benchmarking
    • 9.3.12.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Expansion
  • 9.4.2. Acquisition
  • 9.4.3. Collaborations
  • 9.4.4. Product/service launch
  • 9.4.5. Partnerships
  • 9.4.6. Others